Long-acting lenacapavir in people with multi-drug resistant HIV-1: week 52 results

被引：0

作者：

Ogbuagu, Onyema ^{[1
]}

Segal-Maurer, Sorana ^{[2
]}

Brinson, Cynthia ^{[3
]}

Chetchotisakd, Ploenchan ^{[4
]}

McGowan, Joseph P. ^{[5
]}

Workowski, Kimberly ^{[6
]}

Wang, Hui ^{[7
]}

Margot, Nicolas ^{[7
]}

Dvory-Sobol, Hadas ^{[7
]}

Rhee, Martin S. ^{[7
]}

Baeten, Jared ^{[7
]}

Kabagambe, Samm ^{[8
]}

Molina, Jean-Michel ^{[9
]}

机构：

[1] Yale Univ, Sch Med, New Haven, CT USA

[2] New York Presbyterian Queens, Flushing, NY USA

[3] Cent Texas Clin Res, Austin, TX USA

[4] Srinagarind Hosp, Khon Kaen, Thailand

[5] North Shore Univ Hosp, Manhasset, NY USA

[6] Emory Univ, Atlanta, GA 30322 USA

[7] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[8] Gilead Sci Ltd, London, England

[9] Hop St Louis, Paris, France

来源：

HIV MEDICINE | 2022年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

P006

引用

页码：26 / 27

页数：2

共 50 条

[1] Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 52 Results
Ogbuagu, Onyema
Segal-Maurer, Sorana
Trottier, Benoit
Shirasaka, Takuma
Koenig, Ellen L.
Hoffmann, Christian
Wang, Hui
Margot, Nicolas A.
Dvory-Sobol, Hadas
Rhee, Martin S.
Baeten, Jared
Molina, Jean-Michel
[J]. HIV MEDICINE, 2023, 24 : 59 - 60
[2] Multi-drug resistant HIV-1
Omrani, AS
Pillay, D
[J]. JOURNAL OF INFECTION, 2000, 41 (01) : 5 - 11
[3] Lenacapavir for HIV-1-Potential Promise of a Long-Acting Antiretroviral Drug
Marrazzo, Jeanne
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (19): : 1848 - 1849
[4] Week 52 subgroup efficacy analyses of long-acting subcutaneous lenacapavir in phase II/III in heavily treatment-experienced people with multidrug-resistant HIV (CAPELLA study)
Castagna, A.
Blanco, J.
Hung, C.
Rassool, M.
Ramgopal, M.
Sanchez, W.
Cretico, C.
Hagins, D.
Wheeler, D.
Wang, H.
Henne, I.
Dvory-Sobol, H.
Rhee, M.
Baeten, J.
Onyema, O.
[J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 37 - 38
[5] Tipranavir: a protease inhibitor for multi-drug resistant HIV-1
Best, B
Haubrich, R
[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (01) : 59 - 70
[6] Case Series of People With HIV on the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial
Gandhi, Monica
Hill, Lucas
Grochowski, Janet
Nelson, Alexander
Koss, Catherine A.
Mayorga-Munoz, Francis
Oskarsson, Jon
Shiels, Mary
Avery, Ann
Bamford, Laura
Baron, Jillian
Short, William R.
Hileman, Corrilynn O.
[J]. OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (04):
[7] Cabotegravir plus rilpivirine long-acting as HIV-1 maintenance therapy: ATLAS Week 96 results
Swindells, S.
Lutz, T.
Van Zyl, L.
Porteiro, N.
Benn, P.
Huang, J.
Harrington, C.
Hove, K.
Ford, S.
Talarico, C.
Chounta, V.
Crauwels, H.
Van Solingen-Ristea, R.
Vanveggel, S.
Margolis, D.
Smith, K.
Vandermeulen, K.
Spreen, W.
[J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 19 - 21
[8] Cabotegravir plus rilpivirine long-acting as HIV-1 maintenance therapy: ATLAS week 96 results
Swindells, Susan
Lutz, Thomas
Van Zyl, Lelanie
Porteiro, Norma
Benn, Paul
Huang, Jenny O.
Harrington, Conn M.
Hove, Kai
Ford, Susan L.
Talarico, Christine L.
Chounta, Vasiliki
Crauwels, Herta
Van Solingen-Ristea, Rodica
Vanveggel, Simon
Margolis, David A.
Smith, Kimberly Y.
Vandermeulen, Kati
Spreen, William R.
Baum, Alexander
[J]. INFECTION, 2021, 49 (SUPPL 1) : S7 - S8
[9] Efficacy and safety of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV: week 26 results (Capella study)
Molina, J-M
Segal-Maurer, S.
Stellbrink, H-J
Castagna, A.
Berhe, M.
Richmond, G. J.
Ruane, P. J.
Sinclair, G. I.
Siripassorn, K.
Wang, H.
Patel, H.
Margot, N.
Dvory-Sobol, H.
Hyland, R. H.
Rhee, M. S.
Baeten, J.
DeJesus, E.
[J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24 : 75 - 76
[10] Transmission of Multi-Drug Resistant HIV-1 Despite Antiretroviral Prophylaxis
Soriano, Vicente
[J]. AIDS REVIEWS, 2017, 19 (01) : 55 - 55

← 1 2 3 4 5 →